SpringWorks

The SpringWorks team is excited to be at the German Society for Hematology and Medical Oncology meeting in Cologne, Germany. We look forward to connecting with others who have a shared passion for advancing treatments and improving care for patients living with rare tumors.

Long-term data from the Phase 3 trial of our oral gamma secretase inhibitor for the treatment of #DesmoidTumors were published in @JCO_ASCO. These data reinforce our commitment to making a meaningful difference for patients with rare tumors. Learn more: ms.spr.ly/6010s7xW8

Our team is eager to connect with those who share our passion for advancing treatments and creating possibilities for patients with rare tumors at #ESMO25 in Berlin. Stop by our booth #3031, Hall 3.2 at @myESMO to connect with us and learn more.

We are proud to be a sponsor of the #EANO2025 conference. Our team on the ground looks forward to connecting with others who share our passion for transforming the lives of people affected by NF1-PN. To learn more about us and our work in rare tumors, visit us at Booth 13.

SpringWorks is proud to be a sponsor of the 54th @ChildNeuroSoc Annual Meeting. The conference focuses on childhood-onset neurological and neurodevelopmental conditions, including clinical care and research advances. #CNSAM

That’s a wrap for #DesmoidTumorAwarenessMonth. We are grateful for the opportunity to serve this community and look forward to building on our commitment to these patients and their families across the globe.

Like many other patients living with #DesmoidTumors, Aylin’s path to a diagnosis was lengthy and mentally challenging. Aylin’s resilience and perseverance inspire us to care harder, dig deeper and act with greater urgency. desmoidtumors.com #DesmoidTumorAwarenessMonth

We are excited to kick off #DesmoidTumorAwarnessMonth today! Caroline Daly shares how we are working with global patient advocacy organizations to raise awareness of #DesmoidTumors. Learn more: desmoidtumors.com

We are less than a week away from #DesmoidTumorAwarenessMonth, a time to raise awareness of the devastating impact that these rare tumors can have on patients. Learn more about them at:  desmoidtumors.com

@DTRFoundation Thank you, @DTRFoundation, for your continued advocacy, collaboration and support.

The European Commission approved Ogsiveo® (nirogacestat) as the first treatment for adults with progressing #desmoid tumors: ir.springworkstx.com/news-releases/… Thank you to the @SpringWorksTx team for their dedication to the desmoid tumor community.

The European Commission approved our gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment. Until now, desmoid tumor patients in Europe had no approved treatment options. bit.ly/4fDdzAK #AsOneforPatients

We are honored to be named a #PrixGalien USA nominee for “Best Product for Rare/Orphan Diseases” for our treatment for adults with #DesmoidTumors. We look forward to attending the awards ceremony in October.

#NF1 is a genetic disorder that affects both children and adults. Patients with NF1 have approximately a 30-50% lifetime risk of developing plexiform neurofibromas, or PNs, which are tumors that grow along nerves. Learn more:  nf1pn.com

@OHSUKnight @theNCI @OHSUNews Congratulations on this recognition, Dr. Kummar! Thank you for the work that you do on behalf of those living with desmoid tumors.

Congratulations to Dr. Shivaani Kummar on being honored with the prestigious 2024 @theNCI Director’s Award! 👏 The award is one of the NCI’s highest accolades and is bestowed upon those who demonstrate excellence, innovation, and commitment throughout their organization.

We are excited to share that the European Commission has granted conditional approval for our MEK inhibitor for the treatment of adult and pediatric patients with #NF1-PN. Read more: springworkstx.gcs-web.com/news-releases/…

As of today, SpringWorks Therapeutics is officially a Healthcare company of Merck KGaA, Darmstadt, Germany. Together, we remain focused on helping patients with rare tumors live longer, better lives. Learn more: emdgroup.com/en/news/spring…

Great to share our updated ReNeu data at the 2025 NF Conference. Thank you to @ChildrensTumor for bringing together medical experts across disciplines, patients and caregivers. Together, we can keep transforming outcomes for people with NF. #NFCon2025 #EndNF

We are excited to be at the 2025 @ASCO Meeting in Chicago. If you’re at #ASCO25, stop by our booth (# 23165) to learn more about how we are delivering on our commitment to patients living with rare and devastating diseases.

We are pleased to have received a positive opinion from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) for our MEK inhibitor for the treatment of adults and children with NF1-PN. Read more: ir.springworkstx.com/news-releases/…

We're pleased to share that data from our Phase 2b trial in children and adults with neurofibromatosis type 1 with plexiform neurofibromas (#NF1-PN) will be presented at the @AANmember Annual Meeting. See you there! #AANAM